CENTRALCHINA MT (09982) releases its mid-year performance for 2024, with a net profit of approximately 48.3 million Hong Kong dollars, representing a year-on-year decrease of around 74.7%.
Zhongyuan Jianye (09982) released its performance for the six months ending on June 30, 2024, with the group's revenue totaling 1....
CENTRALCHINA MT (09982) released its performance for the six months ending on June 30, 2024. The group's revenue was RMB 146 million, a year-on-year decrease of 61.8%, and the net profit was approximately HKD 48.3 million, a year-on-year decrease of about 74.7%. Earnings per share were 1.2 cents.
Related Articles
INSILICO (03696) reached global pipeline authorization and AI drug development cooperation with Roche.
CMGE(00302) releases annual performance, with a loss of 1.477 billion yuan, a year-on-year decrease of 30.02%.
JIANGSU EXPRESS (00177) has announced its performance for 2025, with a net profit attributable to shareholders of approximately RMB 4.594 billion, representing a year-on-year decrease of about 7.13%.
INSILICO (03696) reached global pipeline authorization and AI drug development cooperation with Roche.
CMGE(00302) releases annual performance, with a loss of 1.477 billion yuan, a year-on-year decrease of 30.02%.
JIANGSU EXPRESS (00177) has announced its performance for 2025, with a net profit attributable to shareholders of approximately RMB 4.594 billion, representing a year-on-year decrease of about 7.13%.
RECOMMEND
Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026
Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026
Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026
